Shanghai Haohai Biological Technology Co., Ltd. (Stock Code: 6826) reported that on 7 November 2025, its wholly-owned subsidiary, Shanghai Haohai Medical Technology Development Co., Ltd., entered into a Supplemental Equity Transfer Agreement to acquire the remaining 20% equity interest in Shenzhen New Industries Material of Ophthalmology Co., Ltd. (the Target Company) for RMB74 million. Upon completion, Shanghai Haohai Biological Technology Co., Ltd. will hold 100% of the Target Company.

The transaction involves connected persons at the subsidiary level and constitutes a connected transaction under Chapter 14A of the Listing Rules. Since the applicable percentage ratios exceed 0.1% but are below 5%, the deal is subject to reporting and announcement requirements only and is exempt from obtaining independent shareholders’ approval.

According to the announcement, the Target Company’s total assets stood at RMB249,656,230.16 as of 31 December 2024. Its profit after tax for the years ended 31 December 2023 and 31 December 2024 was RMB32,735,000 and RMB22,006,200, respectively, while it recorded RMB16,187,700 for the six months ended 30 June 2025. Management highlighted that the newly determined consideration follows a valuation using a market-based price-to-earnings approach, taking into account changes in the intraocular lens market over the past two years.

Shanghai Haohai Biological Technology Co., Ltd. expects that owning the Target Company outright will help enhance operational efficiency and strengthen its competitiveness in ophthalmology-related products. The acquisition aligns with the company’s broader plan for growth in this segment.